The E2F1/Rb and p53/MDM2 Pathways in DNA Repair and Apoptosis: Understanding the Crosstalk to Develop Novel Strategies for Prostate Cancer Radiotherapy (Q37787401)

From Wikidata

Jump to navigation Jump to search

scientific article published on October 1, 2010

Language	Label	Description	Also known as
English	The E2F1/Rb and p53/MDM2 Pathways in DNA Repair and Apoptosis: Understanding the Crosstalk to Develop Novel Strategies for Prostate Cancer Radiotherapy	scientific article published on October 1, 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

The E2F1/Rb and p53/MDM2 pathways in DNA repair and apoptosis: understanding the crosstalk to develop novel strategies for prostate cancer radiotherapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

The E2F1/Rb and p53/MDM2 Pathways in DNA Repair and Apoptosis: Understanding the Crosstalk to Develop Novel Strategies for Prostate Cancer Radiotherapy (English)

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

apoptotic process

0 references

adaptive radiation therapy

0 references

prostate cancer

1 reference

based on heuristic

inferred from title

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:20832018

10 July 2024

author name string

Thirupandiyur Udayakumar

1

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

Alan Pollack

5

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

Mohammed M. Shareef

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:20832018

10 July 2024

Dayssy A. Diaz

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:20832018

10 July 2024

Mansoor M. Ahmed

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:20832018

10 July 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20832018

10 July 2024

publication date

1 October 2010

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

full work available at URL

https://api.elsevier.com/content/article/PII:S105342961000041X?httpAccept=text/xml

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

https://api.elsevier.com/content/article/PII:S105342961000041X?httpAccept=text/plain

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Seminars in Radiation Oncology

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

20

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

258-266

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

The dark side of a tumor suppressor: anti-apoptotic p53.

1

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

p53 ubiquitination: Mdm2 and beyond

2

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Divorcing ARF and p53: an unsettled case

3

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

The RB and p53 pathways in cancer

5

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

The emerging role of E2F-1 in the DNA damage response and checkpoint control

6

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610

7

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

MDM2 as a predictor of prostate carcinoma outcome: an analysis of Radiation Therapy Oncology Group Protocol 8610.

8

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Loss of p16 expression is of prognostic significance in locally advanced prostate cancer: an analysis from the Radiation Therapy Oncology Group protocol 86-10

9

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202.

10

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation therapy oncology group protocol 86-10.

11

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02.

12

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

A 60 kd MDM2 isoform is produced by caspase cleavage in non-apoptotic tumor cells

13

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Tumour suppression by p53: a role for the DNA damage response?

14

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway

15

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Implication of p53 in base excision DNA repair: in vivo evidence

16

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis

17

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Identification of the mismatch repair genes PMS2 and MLH1 as p53 target genes by using serial analysis of binding elements

18

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Identification of a p53 response element in the promoter region of the hMSH2 gene required for expression in A2780 ovarian cancer cells

19

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

p53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene

20

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Mdm2 regulates p53 mRNA translation through inhibitory interactions with ribosomal protein L26

21

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

E2F1 regulates autophagy and the transcription of autophagy genes

22

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Interaction between ubiquitin-protein ligase SCFSKP2 and E2F-1 underlies the regulation of E2F-1 degradation

23

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

An E2F1-dependent gene expression program that determines the balance between proliferation and cell death

24

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation

25

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Mre11 complex and DNA replication: linkage to E2F and sites of DNA synthesis

26

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Regulation of E2F1 by BRCT Domain-Containing Protein TopBP1

27

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Transcription-independent p53 apoptosis: an alternative route to death

28

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

p53 and E2f: partners in life and death

29

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis

30

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex.

31

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

p53 has a direct apoptogenic role at the mitochondria

32

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis.

33

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

p14ARF links the tumour suppressors RB and p53.

34

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

p14(ARF) regulates E2F activity

35

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Role for the p53 homologue p73 in E2F-1-induced apoptosis

36

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Specificity in the activation and control of transcription factor E2F-dependent apoptosis

37

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization

38

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

p19(ARF) is dispensable for oncogenic stress-induced p53-mediated apoptosis and tumor suppression in vivo

39

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

E2F1 induces phosphorylation of p53 that is coincident with p53 accumulation and apoptosis

40

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

ARF differentially modulates apoptosis induced by E2F1 and Myc.

41

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

ARF is not required for apoptosis in Rb mutant mouse embryos

42

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Adenoviral-E2F-1 radiosensitizes p53wild-type and p53null human prostate cancer cells

43

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Antisense MDM2 enhances E2F1-induced apoptosis and the combination sensitizes androgen-sensitive [corrected] and androgen-insensitive [corrected] prostate cancer cells to radiation

44

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Oncogenic capacity of the E2F1 gene

45

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Novel function of the cyclin A binding site of E2F in regulating p53-induced apoptosis in response to DNA damage

46

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Interaction between the retinoblastoma protein and the oncoprotein MDM2

47

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein

48

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

RB regulates the stability and the apoptotic function of p53 via MDM2

49

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein.

50

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

The central acidic domain of MDM2 is critical in inhibition of retinoblastoma-mediated suppression of E2F and cell growth

51

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy

54

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Mdm2 inhibition of p53 induces E2F1 transactivation via p21.

55

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo.

56

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding.

57

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Therapeutic considerations for Mdm2: not just a one trick pony

58

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Mdm2 promotes genetic instability and transformation independent of p53.

59

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Antisense MDM2 sensitizes prostate cancer cells to androgen deprivation, radiation, and the combination

60

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Predictive models in external beam radiotherapy for clinically localized prostate cancer

61

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10.

62

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Loss of p16 expression is of prognostic significance in locally advanced prostate cancer: an analysis from the Radiation Therapy Oncology Group protocol 86-10

63

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Protein kinase A RI-alpha predicts for prostate cancer outcome: analysis of radiation therapy oncology group trial 86-10.

64

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Prognostic value of survivin in locally advanced prostate cancer: study based on RTOG 8610.

65

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02.

66

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: a study based on RTOG 9202

67

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02.

68

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial

69

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

The importance of protein kinase A in prostate cancer: relationship to patient outcome in Radiation Therapy Oncology Group trial 92-02.

70

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.

71

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer

72

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.

73

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Expression of Bcl-2, p53, and MDM2 in localized prostate cancer with respect to the outcome of radical radiotherapy dose escalation

75

1 reference

10.1016/J.SEMRADONC.2010.05.007

https://api.crossref.org/works/10.1016/J.SEMRADONC.2010.05.007

10 July 2024

Identifiers

10.1016/J.SEMRADONC.2010.05.007

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37787401&oldid=2200620793"